Surgery Partners Earnings Call Balances Growth And Strain

Surgery Partners Inc. ((SGRY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Surgery Partners Inc.’s latest earnings call painted a nuanced picture for investors. Management highlighted solid revenue growth and continued strategic progress, particularly in orthopedics and technology, yet acknowledged that concentrated operational missteps in three hospital markets dragged earnings below expectations and compressed margins, prompting a more cautious near‑term stance.

Revenue Growth

Surgery Partners reported full‑year net revenue of $3.3 billion, up 6.2% from the prior year, underscoring resilient demand across its network. Same‑facility revenue rose 4.9%, signaling that existing centers are still expanding their top line even as the company absorbs operational disruptions in select markets.

Adjusted EBITDA and Margin

Adjusted EBITDA increased 3.5% year over year to $526 million, but profitability lagged revenue momentum. The adjusted EBITDA margin slipped 40 basis points to 15.9%, reflecting cost pressures and weaker performance in a handful of surgical hospitals that offset otherwise stable execution elsewhere in the portfolio.

Case Volume and Specialty Mix

The company performed nearly 670,000 surgical cases in 2025 versus 656,000 in 2024, a modest 2.1% increase that still supports scale benefits. Growth in higher‑value specialties was a bright spot, with more than 42,000 orthopedic cases in the fourth quarter and total joint procedures jumping 15% in Q4 and 19% for the year.

Physician Recruitment and Technology Investment

Management continued to lean into higher‑acuity procedures, recruiting about 700 physicians in 2025 to deepen its clinical bench. The footprint of advanced technology also expanded, with 74 surgical robots in service after adding six during the year, reinforcing the strategy of attracting complex cases and strengthening competitive positioning.

Capital Deployment and M&A Discipline

The company deployed $182 million of acquisition capital in 2025, slightly below its $200 million‑plus target as deal pacing proved slower than planned. Executives emphasized that completed acquisitions met valuation hurdles and that the M&A pipeline remains healthy, while eight de novo facilities, including four in Q4, broadened geographic reach.

Portfolio Optimization Progress

Surgery Partners is actively reshaping its portfolio to enhance earnings quality and balance sheet strength. A notable move is the Baylor Scott & White joint venture in Bryan, Texas, which will deconsolidate that facility but is expected to improve run‑rate earnings efficiency and aligns with management’s goal of resolving key optimization steps by the first half of 2026.

Earnings Shortfall and Concentrated Weakness

Despite solid annual growth metrics, fourth‑quarter performance fell short of even revised expectations, and full‑year adjusted EBITDA was described as significantly below internal targets. Management stressed that the underperformance is concentrated in three surgical hospital markets, rather than indicating a broad deterioration across its ambulatory surgery center network.

Margin Compression

Margin pressure in the fourth quarter proved heavier than anticipated, leaving results weaker than the company’s already lowered third‑quarter outlook. The 40‑basis‑point full‑year margin contraction underscores how localized operational issues and cost rigidity can erode profitability even when revenue trends remain positive.

Payer Mix Pressure and Physician Transitions

Commercial payer mix deteriorated year over year, weighing on average reimbursement levels in affected markets. The shift was linked in part to the departure of seasoned physicians and a wave of new recruits whose practices skew more toward Medicare patients and ramped more slowly than planned, amplifying revenue and margin headwinds.

Operational Cost Dynamics (Labor & Anesthesia)

In the three underperforming surgical hospital markets, labor and anesthesia coverage costs did not adjust quickly enough to the changes in payer mix, creating incremental near‑term margin pressure. Anesthesia dynamics were particularly challenging in hospital settings compared with the ASC portfolio, highlighting the sensitivity of hospital economics to coverage structures and staffing.

Capital Deployment Pace and Execution Risk

The back‑end‑weighted $182 million of capital deployment, below the stated annual goal, also reflects a more measured M&A cadence than originally envisioned. Management acknowledged execution gaps in the second half of 2025, noting the need for cost reductions, leadership changes in certain markets, and targeted operational fixes to restore margin traction.

2026 Outlook and Guidance

For 2026, Surgery Partners issued preliminary guidance for net revenue between $3.3 billion and $3.45 billion, implying single‑digit growth from 2025 levels. The company expects adjusted EBITDA of at least $530 million, or growth of 0.7% or more, and emphasized that this outlook already factors in known headwinds while assuming benefits from portfolio optimization and improved cash conversion.

Surgery Partners’ earnings call ultimately balanced confidence in long‑term growth drivers with candor about immediate operational shortcomings. Revenue expansion, orthopedic momentum, and disciplined capital allocation support the investment case, but fixing issues in a few hospital markets and stabilizing margins will be critical for investors watching whether the 2026 guidance proves conservative or challenging.